Capromorelin

DB15205InvestigationalSmall molecule

Capromorelin is under investigation in clinical trial NCT00527046 (Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults).

Mechanism: Pharmacologically active on Growth hormone secretagogue receptor type 1
Curator reviewed
Formula / weight: C₂₈H₃₅N₅O₄ · 505.619 g/mol (avg)
Also known as: CP-424,391

Resolves to

Compound

UNII0MQ44VUN84CAS193273-66-4ChEMBLCHEMBL113313

Clinical / RWD

RxNorm1986787

Structure

InChIKeyKVLLHLWBPNCVNR-SKCUWOTOSA-NSMILESCN1N=C2CCN(C[C@@]2(CC2=CC=CC=C2)C1=O)C(=O)[C@@H](COCC1=CC=CC=C1)NC(=O)C(C)(C)N

Targets

Q92847GHSR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Capromorelin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account